Study Pre-protocol for 'BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study'

Background Bronchiolitis (most frequently caused by Respiratory Syncytial Virus; RSV) is a common winter disease predominantly affecting children under one year of age. It is a common reason for presentations to an Emergency Department (ED) and frequently results in hospital admission, contributing to paediatric units approaching or exceeding capacity each winter. During the SARS-CoV-2 pandemic, the circulation of RSV was dramatically reduced in the United Kingdom and Ireland. Evidence from the Southern Hemisphere and other European countries suggests that as social distancing restrictions for SARS-CoV-2 are relaxed, RSV infection returns, causing delayed or even summer epidemics, with different age distributions. Study question The ability to track, anticipate and respond to a surge in RSV cases is critical for planning acute care delivery. There is an urgent need to understand the onset of RSV spread at the earliest opportunity. This will influence service planning, to inform clinicians whether the population at risk is a wider age range than normal, and whether there are changes in disease severity. This information is also needed to inform decision on the timing of passive immunisation of children at higher risk of hospitalisation, intensive care admission or death with RSV infection, which is a public health priority. Methods and likely impact This multi-centre prospective observational cohort study will use a well-established research network (Paediatric Emergency Research in the UK and Ireland, PERUKI) to report in real time cases of RSV infection in children aged under two years, through the collection of essential, but non-identifying patient information. Forty centres will gather initial data on age, index of multiple deprivation quintile, clinical features on presentation, and co-morbidities. Each case will be followed up at 7 days to identify treatment, viral diagnosis and outcome. Information be released on a weekly basis and used to support clinical decision making.

antibodies and passive immunity for neonates, and the fact that children born after February 1 0 3 2020 will most likely not have been exposed to circulating RSV, thus reducing adaptive giving a much longer-term burden on health services. The objective of this study is to monitor RSV disease in children under two years of age  This protocol is structured in keeping with the principles of the STROBE statement (strobe-1 1 6 statement.org/). 1 1 7 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 20, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 How the sample is to be selected 1 1 8 A national multi-centre prospective observational cohort study will be carried out through the 1 1 9 PERUKI (Paediatric Emergency Research in the UK and Ireland) Network 13 with forty 1 2 0 departments having committed to participating in the study. All children meeting the 1 2 1 inclusion criteria below will be eligible. Children under two years of age presenting to participating emergency departments with 1 2 4 clinical features of bronchiolitis (cough, tachypnoea or chest recession, and wheeze or 1 2 5 crackles on chest auscultation) 14 or a first episode of acute viral wheeze. Children with previous episodes of wheeze responsive to bronchodilator, suggesting an 1 2 8 underlying diagnosis of recurrent wheeze of early childhood. We will collect data at two time points: baseline (date of presentation to a participating ED)  Clinicians identifying a case for inclusion will keep a local log of participants that contain alone is used in all communication/data entry with the study team. An email after 7 days to 1 3 5 the submitting clinician will prompt data entry at this point. Anonymised data will be entered to a secure online database (REDCap data capture tool) 15,16 1 3 7 (see below), by clinicians providing acute care within the ED. At baseline, data including patient demographics, presenting characteristics, acuity,  At 7 days data will include the child's ultimate outcome (discharged or admitted), highest 1 4 4 acuity dependency (the ward they were placed on if admitted: Normal, High Dependency or 1 4 5 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 20, 2021. laboratory PCR testing, if either is performed as part of standard care. This is a convenience sample cohort study and as such a sample size is not calculated. However, the most recent bronchiolitis peak in France (epidemiological week 13, to 8 April Ireland is 72 million, roughly equivalent to that of France (67 million). The PERUKI sites 1 5 7 already enrolled in this study are estimated to provide care for 25 % of the total paediatric 1 5 8 population, and if a similar trend is seen to France we would therefore expect to recruit 4,000 1 5 9 infants and children in the build up to the peak of an RSV epidemic. By site this would be a 1 6 0 mean of ~100 patients over 3 months, or approximately a patient a day per site. Previous  The trial will be prospectively registered on ISCRTN Registry (https://www.isrctn.com/). To report the timing, frequency and clinical severity of RSV infection in children under two 1 6 8 years of age presenting to hospitals in the UK and Ireland.  ii. To report the geographical timing and spread of RSV infection across the UK. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10. 1101/2021 iii. To identify differences in severity of illness and patient population affected by RSV 1 7 5 in relation to typical seasonal ranges in the published literature. iv. To provide data to support and corroborate current RSV surveillance systems (i.e.

7 7
Respiratory Datamart https://www.gov.uk/government/statistics/national-flu-and-1 7 8 covid-1 9-surveillance-reports) and the Emergency Department Syndromic 1 7 9 Surveillance System (EDSSS).    i. Demographics, regional frequencies, incidence estimates and logistic regression will analysis. This will include: ii. Descriptive statistics 1 9 3 a. Weekly incidence (broken down nationally and regionally) calculated for 1 9 4 population at risk for each Emergency Department.  c. Proportion of RSV vs non-RSV of those tested. with SpO 2 <94% or <92% in room air. ii. Median respiratory rate (with reference to age as per Paediatric Early 2 0 6 Warning Score) at presentation. 17 2 0 7 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 20, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 iii. Blood gas composition (median H+ and pCO2 measurements) at 2 0 8 presentation.    iv. Spatio-temporal dynamics of the 2021 epidemic 2 2 0 a. Travel histories will be used to identify whether RSV is seeded into 2 2 1 community in a number of separate introduction events, or spreads locally. This prospective observational surveillance study needs to be able to rapidly collate data that 2 2 4 will enable other researchers and health services to make informed decisions about the extent 2 2 5 of any RSV surge. For this reason, and the fact that the data being obtained is already 2 2 6 obtained as part of the clinical record, we will not be asking for consent from families and 2 2 7 carers. The clinician will only enter data regarding the outcomes of the child and no 2 2 8 identifying information will be recorded. The patient's study number will be linked to the 2 2 9 local hospital number to allow outcome data to be retrieved. This information will be held by  None of the data recorded centrally by the study team will mean the patient is identifiable, individual child by proxy. This approach has been successfully adopted in other rapidly 2 3 5 deployed studies the authors have been involved in. The security of the REDCap system we 2 3 6 are using to collate data will add additional data protection safeguards.

3 7
The study will be submitted for Integrated Research Application System (IRAS) approval  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 20, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 Data input, storage and management 2 4 0 Anonymised data will be entered using the validated online data entry software REDCap. cleaning. REDCap uses a granular security model so that users can only review the data they feature that records all individual changes with a date/time stamp and a change owner. Data 2 5 5 that are captured and stored will only be available via the information technology systems 2 5 6 linked to the HSCN which is the current validated system used by NHS Trusts to share and 2 5 7 store patient information. Plans for dissemination of the study outcome (including the associated data) once completed. i. Data submissions to the regulatory authorities and local study teams, including an 2 6 2 interactive online dashboard. ii. Conference presentations. iii. Peer reviewed scientific journals. iv. Collaboration with educational websites with international social media reach 2 6 6 (www.dontforgetthebubbles.com). (http://resc-eu.org/).

6 9
Conclusions 2 7 0 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 20, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021